IP Library › Granted Patent US 12,285,608
Granted Patent B2
US 12,285,608 · App. 17/065,162 · Granted Apr 29, 2025

Anatomical targeting of neuromodulation

Inventors: Tianhe Zhang (Studio City, CA); Bradley Lawrence Hershey (Carrollton, TX); Michael A. Moffitt (Solon, OH)
Assignee: Boston Scientific Neuromodulation Corporation
A61N1/36057A61N1/3605A61N1/36062A61N1/36071A61N1/36092A61N1/36103A61N1/36132A61N1/36185A61N1/37247G16H50/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,608
App. No.
17/065,162
Granted
Apr 29, 2025
Kind
B2
Abstract

A neuromodulation targeting system includes a GUI that facilitates selection of one or more neuromodulation target regions. The GUI provides an interactive display representing anatomy of a patient with user-selectable portions corresponding to a plurality of predefined anatomical regions associated with distinct localized clinical effects of neuromodulation. The system further includes a targeting selector engine that is responsive to user selection of a first portion of the interactive display by configuring delivery of neuromodulation therapy to a first target region to produce a first localized clinical effect in the patient at a location corresponding to the first portion of the display, upon administration of the neuromodulation therapy to the patient.

Claims (34)

1. A neuromodulation targeting system facilitating spatial selection of a neuromodulation objective for a neuromodulation therapy to be delivered by a neuromodulation device, the system comprising:

a graphical user interface (GUI) that includes an interactive display representing anatomy of a patient, wherein the interactive display includes user-selectable anatomic sites associated with a plurality of predefined neural pathways corresponding to distinct localized clinical effects of neuromodulation, wherein the interactive display further includes a user-selectable exclusion zone of the anatomy and a therapy type selector input configured for receiving one or more user-selected, specified neuromodulation therapy types from more than one specified neuromodulation therapy types to be excluded from the user-selectable exclusion zone such that the user-selectable exclusion zone of the anatomy of the patient is to be free of the one or more user-selected, specified neuromodulation therapy types, wherein selection of a first anatomic site and selection of the exclusion zone are separate user selections of anatomical regions of the patient; and

a targeting selector engine operatively coupled with the GUI, the targeting selector engine being responsive to selecting the first anatomic site and the exclusion zone to:

computationally determine a first target region where the neuromodulation therapy is to be directed while keeping the user selected exclusion zone free from the one or more specified neuromodulation therapy types and while allowing application of other neuromodulation therapy types in the user selectable exclusion zone, the first target region being distinct from an anatomic location corresponding to the user-selected first anatomic site, and

configure delivery of the neuromodulation therapy by the neuromodulation device to the first target region to produce a first localized clinical effect in the patient at the anatomic location corresponding to the user-selected first anatomic site, upon administration of the neuromodulation therapy to the patient, to achieve the neuromodulation objective.

2. The neuromodulation targeting system of claim 1 , wherein the one or more user-selected, specified neuromodulation therapy types to be excluded from the user-selectable exclusion zone includes suppressive neuromodulation.

3. The neuromodulation targeting system of claim 1 , wherein the one or more user-selected, specified neuromodulation therapy types to be excluded from the user-selectable exclusion zone includes neuromodulation priming.

4. The neuromodulation targeting system of claim 1 , wherein the one or more user-selected, specified neuromodulation therapy types to be excluded from the user-selectable exclusion zone includes more than one neuromodulation therapy type.

5. The neuromodulation targeting system of claim 1 , wherein the interactive display is configured to facilitate the selection of at least one of perceptible neuromodulation, sub-threshold neuromodulation, or priming neuromodulation as the one or more specified neuromodulation therapy types that is to be excluded from the exclusion zone.

6. The neuromodulation targeting system of claim 1 , wherein the neuromodulation therapy includes neuromodulation of brain tissue.

7. The neuromodulation targeting system of claim 1 , wherein the first target region is a neuroanatomic region selected from the group consisting of: a dorsal column region, a dorsal root region, a dorsal horn region, a dermatomic region, or any combination thereof.

8. The neuromodulation targeting system of claim 1 , wherein the interactive display representing the anatomy of the patient is based on actual measured anatomic characteristics of the patient.

9. The neuromodulation targeting system of claim 1 , further comprising:

an electrotherapy parameter selector engine configured to determine an electrical signal waveform to be applied to the first target region, the electrical signal waveform being specific to a neurologic structure present at the first target region.

10. The neuromodulation targeting system of claim 9 , wherein the electrotherapy parameter selector engine is further configured to determine the electrical signal waveform based on an activation function associated with the neurologic structure at the first target region.

11. The neuromodulation targeting system of claim 10 , wherein the electrotherapy parameter selector engine is configured to determine the electrical signal waveform based on an orientation of the neurologic structure at the first target region relative to a location of a set of electrodes from which the neuromodulation therapy is to be directed.

12. The neuromodulation targeting system of claim 9 , wherein the GUI includes a treatment objective input to accept a clinical effect objective specified by a user; and

wherein the electrotherapy parameter selector engine is further configured to determine the electrical signal waveform based on the clinical effect objective.

13. In a neuromodulation targeting system, a method for facilitating spatial selection of a neuromodulation objective, the method comprising:

providing a graphical user interface (GUI) that includes an interactive display representing anatomy of a patient with user-selectable anatomic sites for neuromodulation associated with a plurality of predefined neural pathways corresponding to distinct localized clinical effects of neuromodulation, wherein the interactive display further facilitates selection of an exclusion zone of the anatomy and selection of one or more specified neuromodulation therapy types from more than one specified neuromodulation therapy types to be excluded from the selected exclusion zone such that the exclusion zone of the anatomy of the patient is to be free of the one or more specified neuromodulation therapy types, wherein selection of a first anatomic site and selection of the exclusion zone are distinct user selections of different anatomical regions of the patient and the selection of the exclusion zone indicates that the one or more specified neuromodulation therapy types are prevented from the exclusion zone when neuromodulation is delivered to the anatomic site; and

responding to selecting the first anatomic site and the exclusion zone, including:

computationally determining a first target region where a neuromodulation therapy is to be directed while keeping the user selected exclusion zone free from the one or more specified neuromodulation therapy types and while allowing application of other neuromodulation therapy types in the user selectable exclusion zone, the first target region being distinct from an anatomic location corresponding to the user-selected first anatomic site, and

configuring the neuromodulation therapy for delivery to the first target region to produce a first localized clinical effect in the patient at the anatomic location corresponding to the user-selected first anatomic site, upon administration of the neuromodulation therapy to the patient, to achieve the neuromodulation objective.

14. The method of claim 13 , wherein the neuromodulation therapy includes neuromodulation of brain tissue.

15. The method of claim 13 , wherein the exclusion zone is to be free of suppressive neuromodulation, free of neuromodulation priming, or free of at least two neuromodulation therapy types.

16. The method of claim 13 , wherein the more than one specified neuromodulation therapy types available for selection to be excluded from the exclusion zone include perceptible neuromodulation and sub-perception neuromodulation.

17. A non-transitory machine-readable medium including instructions, which when executed by a machine, cause the machine to perform a method for facilitating spatial selection of a neuromodulation objective, the method comprising:

providing a graphical user interface (GUI) that includes an interactive display representing anatomy of a patient with user-selectable anatomic sites for neuromodulation associated with a plurality of predefined neural pathways corresponding to distinct localized clinical effects of neuromodulation, wherein the interactive display further facilitates selection of an exclusion zone of the anatomy and selection of one or more specified neuromodulation therapy types from more than one specified neuromodulation therapy types to be excluded from the selected exclusion zone such that the exclusion zone of the anatomy of the patient is to be free of the one or more specified neuromodulation therapy types, wherein selection of a first anatomic site and selection of the exclusion zone are distinct user selections of different anatomical regions of the patient and the selection of the exclusion zone indicates that the one or more specified neuromodulation therapy types are prevented from the exclusion zone when neuromodulation is delivered to the anatomic site; and

responding to selecting the first anatomic site and the exclusion zone, including:

computationally determining a first target region where a neuromodulation therapy is to be directed while keeping the user selected exclusion zone free from the one or more specified therapy types of neuromodulation and while allowing application of other neuromodulation therapy types in the user selectable exclusion zone, the first target region being distinct from an anatomic location corresponding to the user-selected first anatomic site, and

configuring the neuromodulation therapy for delivery to the first target region to produce a first localized clinical effect in the patient at the anatomic location corresponding to the user-selected first anatomic site, upon administration of the neuromodulation therapy to the patient, to achieve the neuromodulation objective.

18. The non-transitory machine-readable medium of claim 17 , wherein the neuromodulation therapy includes neuromodulation of brain tissue.

19. The non-transitory machine-readable medium of claim 17 , wherein the exclusion zone is to be free of suppressive neuromodulation, free of neuromodulation priming, or free of all neuromodulation.

20. The non-transitory machine-readable medium of claim 17 , wherein the one or more specified neuromodulation therapy types available for selection to be excluded from the exclusion zone include perceptible neuromodulation and sub-perception neuromodulation.

Continuity (3)
Continuation 15710190 · Sep 20, 2017
Provisional Application 62400472 · Sep 27, 2016
Related Publication 20210016090A1 · Jan 21, 2021
References Cited (62)
US 7333857B2 · Campbell · 2008 [cited by applicant]
US 7933656B2 · Sieracki et al. · 2011 [cited by applicant]
US 8412345B2 · Moffitt · 2013 [cited by applicant]
US 8447408B2 · North et al. · 2013 [cited by applicant]
US 8909350B2 · Lee · 2014 [cited by applicant]
US 8918177B2 · Gauthier · 2014 [cited by applicant]
US 9044610B2 · Rosenberg et al. · 2015 [cited by applicant]
US 9737715B2 · Moffitt et al. · 2017 [cited by applicant]
US 10076664B1 · Thacker et al. · 2018 [cited by applicant]
US 10850101B2 · Zhang et al. · 2020 [cited by applicant]
US 20040098063A1 · Goetz · 2004 [cited by examiner]
US 20070203544A1 · Goetz et al. · 2007 [cited by applicant]
US 20070203545A1 · Stone · 2007 [cited by examiner]
US 20080064947A1 · Heruth et al. · 2008 [cited by applicant]
US 20090287271A1 · Blum et al. · 2009 [cited by applicant]
US 20100010566A1 · Thacker · 2010 [cited by examiner]
US 20120083857A1 · Bradley · 2012 [cited by applicant]
US 20120239109A1 · Lee · 2012 [cited by applicant]
US 20120265268A1 · Blum et al. · 2012 [cited by applicant]
US 20130060300A1 · Polefko et al. · 2013 [cited by applicant]
US 20130261697A1 · Parker · 2013 [cited by applicant]
US 20130268026A1 · Rao et al. · 2013 [cited by applicant]
US 20130325084A1 · Lee · 2013 [cited by examiner]
US 20140155953A1 · Wacnik et al. · 2014 [cited by applicant]
US 20150066111A1 · Blum et al. · 2015 [cited by applicant]
US 20160082252A1 · Hershey et al. · 2016 [cited by applicant]
US 20160228706A1 · Hershey et al. · 2016 [cited by applicant]
US 20180085583A1 · Zhang et al. · 2018 [cited by applicant]
US 20190009094A1 · Zhang et al. · 2019 [cited by applicant]
EP 3519036B1 · 2023 [cited by applicant]
WO WO2007097859A1 · 2007 [cited by applicant]
WO WO2018063879A1 · 2018 [cited by applicant]
WO WO2019010225A1 · 2019 [cited by applicant]
“U.S. Appl. No. 15/710,190, Final Office Action mailed May 8, 2020”, 21 pgs. [cited by applicant]
“U.S. Appl. No. 15/710, 190, Non Final Office Action mailed Dec. 12, 2019”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 15/710,190, Notice of Allowance mailed Jul. 30, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 15/710,190, Response filed Feb. 28, 2020 to Non Final Office Action mailed Dec. 12, 2019”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 15/710,190, Response filed Jul. 6, 2020 to Final Office Action mailed May 8, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Advisory Action mailed Sep. 21, 2020”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Final Office Action mailed Jul. 14, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Non Final Office Action mailed Feb. 6, 2020”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Response Filed Apr. 23, 2020 to Non Final Office Action mailed Feb. 6, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Response filed Sep. 11, 2020 to Final Office Action mailed Jul. 14, 2020”, 13 pgs. [cited by applicant]
“European Application Serial No. 1777752.1, Response to Communication pursuant to Rules 161 and 162 filed Dec. 4, 2019”, 9 pgs. [cited by applicant]
“European Application Serial No. 18746059.7, Response to Communication Pursuant to Rules 161 and 162 filed Aug. 12, 2020”, 16 pgs. [cited by applicant]
“International Application Serial No. PCT/US2017/052440, International Preliminary Report on Patentability mailed Apr. 11, 2019”, 8 pgs. [cited by applicant]
“International Application Serial No. PCT/US2017/052440, International Search Report mailed Dec. 15, 2017”, 3 pgs. [cited by applicant]
“International Application Serial No. PCT/US2017/052440, Written Opinion mailed Dec. 15, 2017”, 6 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/040788, International Preliminary Report on Patentability mailed Jan. 16, 2020”, 8 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/040788, International Search Report mailed Oct. 30, 2018”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/040788, Written Opinion mailed Oct. 30, 2018”, 6 pgs. [cited by applicant]
“Medtronic Programming Guide, Neurostimulators for Chronic Pain”, UC201203811a EN © 2013 Medtronic, Inc., 1-130. [cited by applicant]
Howell, Bryan, et al., “Evaluation of Intradural Stimulation Efficiency and Selectivity in a Computational Model of Spinal Cord Stimulation”, PLOS One; DOI:10.1371/journal.pone.0114938, (Dec. 23, 2014), 1-25. [cited by applicant]
Richard, B North et al., “Spinal Cord Stimulator Adjustment to Maximize Implanted Battery Longevity: A Randomized Controlled Trial Using a Computerized, Patient-Interactive Programmer”, Neuromudulation: Technology at th… [cited by applicant]
U.S. Appl. No. 15/710,190, filed Sep. 20, 2017, Anatomical Targeting of Neuromodulation. [cited by applicant]
U.S. Appl. No. 16/027,040, filed Jul. 3, 2018, Method and Apparatus for Selecting Stimulation Configuration and Target for Neuromodulation. [cited by applicant]
“U.S. Appl. No. 16/027,040, Examiner Interview Summary mailed Mar. 30, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Final Office Action mailed Jun. 1, 2021”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Non Final Office Action mailed Dec. 28, 2020”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/027,040, Response filed Mar. 25, 2021 to Non Final Office Action mailed Dec. 28, 2020”, 14 pgs. [cited by applicant]
“European Application Serial No. 17777752.1, Communication Pursuant to Article 94(3) EPC mailed Jul. 5, 2022”, 4 pgs. [cited by applicant]
“European Application Serial No. 17777752.1, Response filed Nov. 8, 2022 to Communication Pursuant to Article 94(3) EPC mailed Jul. 5, 2022”, 8 pgs. [cited by applicant]